[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-diseases":689},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,46,99,126,155,181,202,229,253,283,303,333,361,398,418,439,463,491,536,554,576,596,616,638,663],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100521353",false,"NCT06068491","Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)","Integrating Veteran-Centered Care for Advanced Liver Disease (I-VCALD)","Vet-CALD","Inclusion Criteria:\n\n* Patients will be between 18 and 80 years of age\n* Patients must be Veterans\n* Patients must have been in care at one of the recruiting sites with 1 or more encounters in primary care or GI\u002FHepatology in the last 24 months\n* Patients must have advanced liver disease, defined by ICD-10 codes for cirrhosis complications (ever) or MELD 3.0 \\>12 or MELD-Na \\>12 or Fibroscan LSM \\>20kpa\n\nExclusion Criteria:\n\n* Non-Veteran patients\n* Patients who do not speak English, do not have access to a telephone or computers, have cognitive impairments, or who are unable to complete a valid informed consent form after three attempts\n* Patients who have already made significant progress toward our endpoints: a) with prior history of liver transplantation, or b) on the liver transplant waiting list, or c) had formal evaluation for liver transplantation in the past 3 years\n* Patients with very limited life expectancy (advanced cancer, acute-on-chronic liver failure, and hospice patients)\n* Patients hospitalized, or in long term facilities or nursing homes at the time they meet inclusion criteria\n* Patients with chart diagnosis of uncontrolled mental health or schizophrenia","ALL","18 Years","80 Years",{"count":21,"type":22},450,"ESTIMATED","INTERVENTIONAL",[25],"NA","Advanced liver disease is a serious illness that disproportionately affects Veterans, many of whom hope for curative liver transplantation. However, too few receive a transplant and most continue to suffer from increasing symptoms and hospitalizations. The proposed project uses a whole person, Veteran-centered approach that identifies Veterans with advanced liver disease using a population-based health management system and integrates curative and early supportive care using a telemedicine-based nurse care counselor to (1) discuss patient's understanding of illness severity and prognosis, (2) identify priorities and care preferences and (3) align curative and supportive care options to achieve patient priorities. Study outcomes include changes in (1) rates of consideration for liver transplantation, and (2) completion of serious illness discussions. Findings will inform adaptations to the intervention and facilitators for its dissemination.",[28],"Liver Diseases",[30,31,32],"Patient-Centered Care","Randomized Controlled Trial","Delivery of Healthcare, Integrated","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2024-10-01",{"date":41,"type":22},"2027-09-30",{"name":43,"class":44},"VA Office of Research and Development","FED",8,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":75,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist",{"count":53,"type":22},132,[25],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[57,28,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74],"Obesity","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[76,77,78,79,80,81,82,83,84,85,86,87,88],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","2026-06-23",{"date":36,"type":37},{"date":92,"type":37},"2025-06-24",{"date":94,"type":22},"2028-06",{"name":96,"class":97},"Pichamol Jirapinyo, MD, MPH","OTHER",2,{"id":100,"slug":4,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100635960","NCT07559474","A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment","A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment","Inclusion Criteria:\n\n* Ability to comprehend and willingness to sign a written ICF for the study.\n* Aged 18 to 80 years, inclusive, at the time of signing the ICF.\n* Moderate or severe hepatic impairment based on CP score.\n* Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.\n* Body mass index of 18.0 to 43.0 kg\u002Fm2 (inclusive).\n* Willingness to avoid pregnancy or fathering children.\n\nExclusion Criteria:\n\n* Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.\n* Tobacco or nicotine-containing product use of \\> 10 cigarettes per day within 1 month before screening.\n* Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.\n* Participants who have a history of paracentesis within 2 months prior to check-in.\n* Participants who required new medication or an increase in dose for hepatic encephalopathy within 3 months prior to check-in.\n* Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor. Participants who have a portal systemic shunt. Up to 3 participants with transjugular intrahepatic portosystemic shunt may be included.\n* Participants who had esophageal banding within 3 months prior to check-in or required any other treatment for gastrointestinal bleeding within 6 months prior to check-in.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria may apply.",{"count":106,"type":22},16,[108],"PHASE1","This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.",[111,28],"Hepatic Insufficiency",[113,114],"hepatic impairment","liver impairment (moderate and severe)","2026-06-12",{"date":117,"type":37},"2026-06-16",{"date":119,"type":37},"2026-05-27",{"date":121,"type":22},"2027-04-13",{"name":123,"class":124},"Incyte Corporation","INDUSTRY",4,{"id":127,"slug":4,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100643365","NCT07634939","Liver Micro Flow - MRI","Magnetic Resonance Imaging (MRI)-Based Quantification of Perfusion and Microstructure","Inclusion Criteria (Healthy Volunteers):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n\nExclusion Criteria (Healthy Volunteers):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nInclusion Criteria (Participants with CLD):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n* Clinical evidence of MASLD, MASH, cirrhosis or liver fibrosis\n\nExclusion Criteria (Participants with CLD):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nInclusion Criteria (Liver Fibrosis Spectrum):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n* Known or suspected liver steatosis, steatohepatitis, fibrosis, cirrhosis, or portal hypertension, based on clinical imaging from the previous 6 months or histology over the previous 12 months.\n\n  * At least N=50 will be selected based on having a clinically indicated liver biopsy\n* If taking beta blocker medication, willing to temporarily discontinue the medication for three days prior to the research visit after providing informed consent and in consultation with their treating physician.\n\nExclusion Criteria (Liver Fibrosis Spectrum):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver",true,"7 Years",{"count":135,"type":22},110,"OBSERVATIONAL","This study integrates and evaluates a series of novel MRI methods for quantifying blood perfusion and tissue microstructure. The proposed perfusion and microstructure measures may provide biomarkers for fibrosis, cirrhosis, portal hypertension, and response to treatment. The precision of these methods will be evaluated in 110 participants, including healthy volunteers, people with chronic liver disease (CLD), and people with liver fibrosis.",[28],[140,141,142,143],"MRI","IVIM","tissue perfusion","microstructure","NOT_YET_RECRUITING","2026-06-08",{"date":147,"type":37},"2026-06-10",{"date":149,"type":22},"2026-07-01",{"date":151,"type":22},"2029-05",{"name":153,"class":97},"University of Wisconsin, Madison",1,{"id":156,"slug":4,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100376409","NCT04181138","Primary Sclerosing Cholangitis in Children","Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children","Inclusion Criteria:\n\nPatients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment.\n\nIndividuals must meet all of the Inclusion criteria in order to be eligible to participate in the study:\n\n1. Aged 2 through 25 years at time of screening.\n2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:\n\n   * Focal structuring of the bile duct(s)\n   * Dominant stricture of the common bile duct\n   * Saccular dilatation of bile duct(s)\n   * Beaded appearance of bile duct(s)\n   * Pruning appearance of the distal bile duct branches\n\n   AND\u002FOR\n3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:\n\n   * Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR...\n   * Definitive small duct PSC: Periductal fibrosis\u002F \"onion skinning\" around interlobular bile ducts or smaller profiles\n4. Stated willingness to comply with all study procedures and availability for the duration of the study.\n5. Able to provide informed consent\u002Fassent\n\nParticipants for the imaging study are eligible if they are:\n\n1. Aged 8 through 25 years at the time of screening\n2. No absolute contraindication to MRI\n3. No skin condition that could be aggravated by MREL\n4. Meet all other eligibility criteria of the PSC Observational Study\n5. For whom none of the exclusion criteria apply\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria at baseline will be excluded from participation in this study.\n\n1. History of liver transplantation\n2. History bone marrow transplantation\n3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV\u002FAIDS\n4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)\n5. History of ischemic cholangitis\n6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy\n7. History of recurrent pyogenic cholangitis\n8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram\u002Fliver biopsy evaluated to determine enrollment\n9. History of biliary tract surgery for choledochal cyst\n10. History of hepatocellular carcinoma, or hepatoblastoma\n11. History of surgical biliary trauma\n12. History of congenital cytomegalovirus (CMV) hepatitis\n13. History of Sickle Cell Disease\n14. History of cystic fibrosis, biliary atresia, Caroli disease\u002Fcongenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3\u002FMDR3 disease\n15. History of cardiac hepatopathy.\n16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency\n17. Diagnosis of systemic lupus erythematosus (SLE)\n18. Concurrent pregnancy at the time of enrollment -","2 Years","25 Years",{"count":164,"type":22},1000,"Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.\n\nThe purposes of this study are to:\n\n* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.\n* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning\n* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.",[167,28,168],"Primary Sclerosing Cholangitis","Cholangitis, Sclerosing",[170,167],"Pediatric Liver Disease","2026-06-03",{"date":173,"type":37},"2026-06-04",{"date":175,"type":37},"2021-12-30",{"date":177,"type":22},"2029-05-31",{"name":179,"class":97},"Arbor Research Collaborative for Health",12,{"id":182,"slug":4,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":154},"100345145","NCT03773887","Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease","TargetOH","Inclusion Criteria:\n\n* group A: patients with acute alcoholic hepatitis\n* Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to admission (\\> 60 g per day for men and\\> 40 g per day for women)\n* Moderate elevation of transaminases (less than 500 U \u002F L) with a typical ASAT \u002F ALAT ratio of 2: 1\n* Bilirubin\\> 50 mg \u002F l\n* Absence of autoimmune liver disease (ANA \\\u003C1\u002F80, AML \\\u003C1\u002F80, LKM1 neg, AAM neg)\n* Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative HBsAg, negative HCV PCR)\n* Patients with other acute complications than alcoholic hepatitis may be included (eg, digestive hemorrhage, acute renal failure, infection, etc.)\n* Because there is no validated noninvasive tool for the diagnosis of alcoholic hepatitis, histological confirmation is required in all patients (preferably by transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the following histological characteristics: Hepatocellular lesions (ballooning, Mallory body)\u002F Inflammatory infiltrate with polymorphonuclear neutrophils\n* group B1: patients with alcoholic cirrhosis\n* Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments (www.has-sante.fr)\n* group B2: patients free from chronic liver disease\n* Justification of blood and liver sampling for the management of a pathology other than chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy liver)\n\nExclusion Criteria:\n\n* For groups A and B1:\n* Patients with hepatocellular carcinoma of progressive non-hepatic cancer\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy\n* for group B2:\n* Alcoholic liver disease\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy","70 Years",{"count":21,"type":22},[25],"The main objective of this study is the comparison of the profile of the pro-inflammatory cytokines at the patients suffering from an alcoholic hepatitis to that of two groups witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic liver disease",[28,192],"Acute on Chronic Hepatic Failure","2026-05-20",{"date":195,"type":37},"2026-05-22",{"date":197,"type":37},"2014-12-25",{"date":199,"type":22},"2027-09",{"name":201,"class":97},"University Hospital, Lille",{"id":203,"slug":4,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":207,"targetDuration":209,"studyType":136,"phases":4,"briefSummary":210,"conditions":211,"keywords":217,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":228},"100637253","NCT07602504","China Metastatic Liver Cancer Clinical Registry Cohort Database","Inclusion Criteria:\n\n1. Patients with histologically or radiologically confirmed metastatic liver cancer.\n2. Age ≥ 18 years.\n3. Patients who have voluntarily signed the informed consent form.\n4. Patients with complete baseline clinical data.\n\nExclusion Criteria:\n\n1. Patients with primary liver cancer (e.g., hepatocellular carcinoma).\n2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.\n3. Patients who have previously participated in other interventional clinical trials.\n4. Patients with severe cognitive disorders or communication barriers that prevent informed consent.\n5. Patients with incomplete or missing key clinical data.",{"count":208,"type":22},2000,"10 Years","This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.",[212,213,214,215,28,216],"Liver Metastases","Metastases to Liver","Liver Cancer","Neoplasms","Colorectal Cancer Metastatic",[218],"Liver Metastases; Metastatic Colorectal Cancer","2026-05-16",{"date":195,"type":37},{"date":222,"type":22},"2026-06-01",{"date":224,"type":22},"2036-05-31",{"name":226,"class":227},"Anhui Provincial Hospital","OTHER_GOV",3,{"id":230,"slug":4,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":154},"100633285","NCT07524699","A Study About Remote and Local Liver Surgery","Efficacy and Safety of MP1000 System in Remote and Local Liver Surgery: A Prospective, Multicenter, Single-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age range: 18-75 years old (inclusive), gender not restricted;\n2. BMI: 18-30 Kg\u002Fm2;\n3. Relevant indications for liver surgery;\n4. Physiological condition allows for laparoscopic surgery, and the Iwate score for laparoscopic difficulty of the enrolled patients is ≤ 6;\n5. Willing to cooperate and complete follow-up and related subsequent examinations;\n6. Voluntary to sign the informed consent form;\n7. Indocyanine green 15-minute retention rate (ICG-R15) \\\u003C 15%, and liver function Child-Pugh grade is A.\n\nExclusion Criteria:\n\n1. Patients with severe circulatory system diseases who cannot tolerate surgery;\n2. Pregnant or lactating women;\n3. Patients with a history of epilepsy or mental illness;\n4. Patients with severe allergic constitution and those suspected or diagnosed with alcohol or drug addiction;\n5. Patients who cannot understand the research requirements or who cannot complete the research follow-up;\n6. Patients considered unsuitable to participate in this trial by the researchers.","75 Years",{"count":237,"type":22},148,[25],"The goal of this clinical trial is to learn if the robotic surgical system producted by Shenzhen Edge Medical Company has a non-inferior textbook outcome in liver surgery in the field of remote surgery compared to local robotic surgery. It will also learn about the safety of remote liver surgery.\n\nThe main questions are: Does remote liver surgery not lower the textbook outcomes in liver surgery compared to the local robotic surgery? What complications do participants have when taking remote liver surgery? Investigators will compare remote liver surgery to local robotic liver surgery to see if remote liver surgery doesn't lower the textbook outcome in liver surgery.\n\nParticipants will:\n\nUndergo remote or local robotic liver surgery according to the random program; Visit the clinic in 3, 28 and 42 day after surgery for checkups and tests; Keep a diary of their postoperative complications.",[28],[242,243,244],"Remote Surgery","Liver Surgery","Randomized controlled trial","2026-05-13",{"date":247,"type":37},"2026-05-18",{"date":219,"type":22},{"date":250,"type":22},"2028-07-31",{"name":252,"class":97},"Tongji Hospital",{"id":254,"slug":4,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100601487","NCT07111130","Restoring Bile Acid Homeostasis Via Lifestyle Adjustments to Prevent the Development of Liver Cancer","Prospective Interventional Study Evaluating the Modulation of Bile Acid Profiles, Gut Microbiome and Liver Health Through Lifestyle Adjustments in Individuals at High Risk of Developing Liver Cancer.","RE-BALANCE","Inclusion Criteria:\n\nThe following criteria are to be checked at the time of enrolment. The patient may only be included in the study if ALL of the following statements are FULFILLED:\n\n1. The patient is an existing participant of the ELEGANCE study and shows no evidence of hepatocellular carcinoma (HCC) at the time of enrolment into RE-BALANCE.\n2. Male and female patients aged 50 to 90 years at the time of informed consent are eligible. However, patients with cirrhosis may be included if they are aged 40 to 90 years.\n3. Negative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody\n4. High-risk bile acid profile, defined as a 12-non-hydroxy\u002F12-hydroxy bile acid ratio below the threshold determined from ELEGANCE cohort data.\n5. Patient is able to comply with scheduled visits, assessments and other study procedures.\n6. Patient is willing to provide informed consent before enrolment in the study.\n\nExclusion Criteria:\n\nThe following criteria should be checked at the time of enrolment. If ANY applies, the patient must not be included in the study:\n\n1. Patient with confirmed diagnosis of HCC by the American Association for the Study of the Liver Disease (AASLD) imaging criteria or histology \u002F cytology within the last 5 years.\n2. Patient with Child Pugh C or decompensated cirrhosis at time of enrolment (based on the judgement of the Investigator).\n3. Patient with active hepatic encephalopathy at time of enrolment.\n4. Patient is known to be positive for the Human Immunodeficiency Virus (HIV).\n5. Patient has chronic liver diseases apart from steatosis or compensated cirrhosis (e.g., autoimmune hepatitis, primary biliary cholangitis. etc.).\n6. Uncontrolled diabetes mellitus requiring special dietary management or persistent unacceptable HbA1c levels.\n7. Use of weight-loss medications (e.g., GLP-1 agonists, Orlistat) within three months prior to enrolment or planned use during the study period.\n8. History of bariatric surgery or planned bariatric surgery during the study period.\n9. Patient has significant comorbidities expected to limit life expectancy to less than one year, or that would render diet or exercise unsafe\n\n   1. Diseases involving muscles, bones or joints that may impact the subjects' performance during exercise testing and exercise rehabilitation\n   2. Co-morbidities that may adversely affect exercise performance\n   3. Requiring an assistive aid with walking\n   4. Conditions that require strict dietary restrictions or impair ability to follow dietary interventions\n10. Patient has significant gastrointestinal diseases affecting nutrient absorption or requiring a special diet incompatible with study diet.\n11. Pregnancy or breastfeeding\n12. Current use of medications or supplements that significantly alter bile acid gastrointestinal absorption (e.g., bile acid sequestrants) that cannot be safely discontinued.\n13. Patient has severe food allergies or intolerances incompatible with the provided study diet.\n14. Patient has psychiatric or addictive disorders that may compromise his\u002Fher ability to give informed consent, or to comply with the study procedures.\n15. Patient is unable to provide informed consent or refuse blood taking and other investigations including LMS scans.\n16. Patient has any other condition which, in the opinion of the Investigators, would make the patient unsuitable for enrolment or could interfere with completion of the study.","40 Years","90 Years",{"count":263,"type":22},90,[25],"This is a prospective, single-arm, non-randomized interventional study nested within the existing ELEGANCE cohort. Patients eligible for the RE-BALANCE study will be selected from the ELEGANCE cohort based on predefined high-risk criteria, specifically a low 12-non-hydroxy\u002F12-hydroxy bile acid ratio indicative of elevated hepatocarcinogenic risk.\n\nThe study comprises Baseline Assessments (Visit 1), Intervention Visits (Visit 2-8), and Follow-up Assessments (Visit 9-11).",[28],[268,269,270,271,272],"Hepatocellular Carcinoma (HCC)","Non-viral HCC","Interventional Study","Lifestyle Adjustments","Bile Acid, Microbiome and Liver Health Modulation","2026-05-12",{"date":275,"type":37},"2026-05-15",{"date":277,"type":22},"2026-07",{"date":279,"type":22},"2028-03",{"name":281,"class":97},"National Cancer Centre, Singapore",14,{"id":284,"slug":4,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":154},"100604523","NCT07150624","The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine","Polyene Phosphatidylcholine Injection for the Treatment of Perioperative Liver Injury With Laparoscopic Hepatectomy in Hepatocellular Carcinoma: a Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection.\n2. Surgical scope (defined by randomization stratification):Stratum 1: Major hepatectomy, involving the resection of at least 3 Couinaud liver segments, including right hemihepatectomy and extended right hemihepatectomy, etc.Stratum 2: Minor hepatectomy, involving the resection of no more than 2 Couinaud liver segments. This includes right posterior sectorectomy, right anterior sectorectomy, left lateral sectionectomy, single segmentectomy, etc.\n3. During the operation, the Pringle method is used to block the first hepatic portal. Each block lasts ≤ 15 minutes, and the blocking procedure is performed 2 to 4 times.\n4. Age: 18 - 80 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg\u002Fm².\n5. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III.\n6. Preoperative ICG R15 \\\u003C 10%, and the residual liver volume\u002Fstandard liver volume \\> 40%.\n7. A single HCC (hepatocellular carcinoma), with a tumor diameter of less than 10 cm, without distant metastasis or invasion of the portal vein system.\n8. Preoperative ALT \\\u003C 2x ULN (upper limit of normal).\n9. No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed \\> 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed \\> 4 weeks ago.\n10. No liver-damaging treatment drugs were used within two weeks prior to enrollment.\n\nExclusion Criteria:\n\n1. Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc\n2. Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds)\n3. Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses\n4. During the operation, microwave treatment or a combination of microwave treatment was adopted\n5. More than 4 times of blocking at the first hepatic hilum, or a single blocking duration longer than 15 minutes\n6. Non-anatomic liver resection, where the remaining liver contains large areas of ischemic\u002Fedematous regions\n7. More than 1000ml of blood transfusion during the operation\n8. During the operation, an extra-hepatic disease was discovered. Other organs except the gallbladder needed to be removed simultaneously\n9. During the operation, other intrahepatic lesions were discovered, which required combination with other surgeries, such as ablation or choledochojejunostomy\n10. Diseases that have previously received systemic treatment with glucocorticoids, such as chronic kidney disease, inflammatory diseases, or other immune system-related disorders\n11. Psychosis, severe neurosis, those who cannot cooperate with this experiment\n12. Participated in other clinical trials within the previous 3 months before enrollment\n13. Allergy or intolerance to benzoic acid, or to the study drug\n14. Pregnant and lactating women\n15. The researchers believe that any participants who have any other factors that would make them unsuitable for this trial should not be included",{"count":290,"type":22},96,[292],"PHASE4","A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma were compared.",[268,28],"2026-05-06",{"date":297,"type":37},"2026-05-11",{"date":299,"type":37},"2025-11-10",{"date":301,"type":22},"2026-12-31",{"name":226,"class":227},{"id":304,"slug":4,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":312,"conditions":313,"keywords":317,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":154},"100595104","NCT07028112","Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.","Impact de la Surcharge en Fer Sur l'Incidence Des Complications hépatiques Chez Les Patients allogreffés de Cellules Souches hématopoïétiques à Plus de 10 Ans de la Greffe","AlloFer","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Allogeneic HSCT performed at Hôpital Saint Louis between 2004\u002F01\u002F01 and 2014\u002F12\u002F31\n* Alive and attending routine annual follow up within the two years of the study\n* Having given his non-opposition to study after understand overall aims\n* With health insurance coverage\n* Follow up consultation at Saint-Louis Hospital\n\nExclusion Criteria:\n\n* Patient under legal protection (protection of the court, or in curatorship or guardianship).\n\nnot in relapse of the hematological disease at the time of inclusion.\n\n• Patients under 45 Kg",{"count":311,"type":22},500,"This single-center, non interventional cohort study investigates whether chronic iron overload influences the incidence of liver complications in adults who are at least 10 years beyond allogeneic hematopoietic stem cell transplantation (allo HSCT). Approximately 400-500 survivors transplanted at Hôpital Saint Louis between January 2004 and December 2014 will be evaluated. Transplant characteristics, prior iron overload therapy, and historical hepatic events will be collected through the Promise database. At the same time, the prospective visit will include laboratory panels and non invasive liver stiffness measurement by FibroScan or shear wave elastography. The study's primary objective is to assess the impact of iron overload on the incidence of hepatic complications in patients more than 10 years after an allogeneic hematopoietic stem cell transplantation. Secondary aims include describing the spectrum and frequency of hepatic complications, determining risk factors (including graft versus host disease, conditioning regimen, and comorbidities), and evaluating the long term effectiveness of previous iron reduction treatments (phlebotomy or chelation). Results will clarify whether monitoring and treating iron overload in long term allo HSCT survivors can prevent late hepatic morbidity.",[314,315,28,316],"Iron Overload","Hemosiderosis","Hematopoietic Stem Cell Transplantation (HSCT)",[318,319,320,321,322,323],"Iron overload","Liver fibrosis","Elastography","Long-term complications","Allogeneic hematopoietic stem-cell transplantation","graft-versus-host disease","2026-04-22",{"date":326,"type":37},"2026-04-27",{"date":328,"type":37},"2025-08-20",{"date":330,"type":22},"2027-08-20",{"name":332,"class":97},"Assistance Publique - Hôpitaux de Paris",{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":360},"100583282","NCT06874296","Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time","Pilot, Open, Prospective, Randomized, Multicenter Trial On Quality Assessment Of Declined Liver Grafts By Normothermic Ex Vivo Machine Perfusion For Decreasing Time To Transplantation","ExTra","Inclusion Criteria:\n\n* Able to consent\n* ≥ 18 years old\n* Listed in status \"transplantable\" by the transplant conference of the study centre for liver transplantation, according to the guidelines of the German Medical Association valid at the time of inclusion\n* ReMELD-Na-Score ≤ 21 (equivalent to MELD ≤25), not eligible for \\[non\\]standard exceptions\n* Medically suitable and informed for transplantation with an organ that fulfils extended donor criteria (Eurotransplant ECD criteria)\n* Patient information and written consent to participate in the Extra trial\n* No participation in another interventional study during participation\n\nExclusion Criteria:\n\n* Listed for retransplantation\n* High-Urgency Listing\n* Listed for combined organ transplantation\n* Pregnancy",{"count":341,"type":22},186,[25],"The goal of this study is to find out if quality assessment by normothermic machine perfusion can be used to safely increase the number of usable donor livers, helping more people get transplants faster and with better results. This process keeps a donated liver working outside the body before transplantation, allowing surgeons to assess whether livers previously considered unsuitable can still be used.\n\nThe main questions this study aims to answer are:\n\n* Does this method help patients get a transplant sooner?\n* Can this method make more livers available for transplant?\n* Does it improve survival and health after transplant?\n\nParticipants in this study must be on the waiting list for a liver transplant with a ReMELD-Na-Score of 21 or less (equivalent to MELD ≤25) and must not qualify for certain special exceptions. Participants will be randomly placed into one of two groups:\n\n* Experimental group: In addition to regular organ offers, these participants may receive a liver that was initially not considered for transplantation but meets quality standards after at least four hours of machine perfusion.\n* Control group: These participants will receive a liver through the usual transplant process.\n\nThe main measure of success is how quickly participants receive a transplant. Researchers will also look at other important factors, such as survival rates, quality of life, hospital stay, and complications after transplant.\n\nThis study may help improve liver transplantation by making better use of available donor livers, reducing waiting times, and improving patient outcomes.",[345,28,346],"Liver Transplantation","Surgery",[345,348,349,350],"Extended Criteria Donors","Normothermic Machine Perfusion","Discarded Liver Grafts","2026-04-14",{"date":353,"type":37},"2026-04-15",{"date":355,"type":37},"2025-06-02",{"date":357,"type":22},"2030-12-31",{"name":359,"class":97},"Charite University, Berlin, Germany",10,{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":132,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":397},"100083612","NCT00345930","DILIN - Prospective Study","A Multi-Center, Longitudinal Study of Drug-and CAM-Induced Liver Injury","Inclusion Criteria:\n\n* Age \\> 2 years at enrollment into the study.\n* Evidence of liver injury that is known or suspected to be related to consumption of a drug or CAM product in the 6-month period prior to enrollment.\n* Written Informed consent from the patient or the patient's legal guardian.\n* Documented clinically important DILI, defined as any of the following:\n\n  1. ALT or AST \\>5 x ULN or A P'ase \\>2 x ULN confirmed on at least 2 consecutive blood draws in patients with previously normal values.\n  2. If baseline (BL) ALT, AST or A P'ase are known to be elevated, then ALT or AST \\>5 x BL or A P'ase \\>2 x BL on at least 2 consecutive blood draws. \"Baseline\" is defined as the average of at least 2 measurements performed during the 12-month period prior to starting the DILI medication.\n  3. Any elevation of ALT, A P'ase, or AST, associated with (a) increased total bilirubin \\[ ≥ 2.5 mg\u002FdL\\], in absence of prior diagnosis of liver disease, Gilbert's syndrome, or evidence of hemolysis or (b) coagulopathy with INR \\> 1.5 in absence of coumadin therapy or known vitamin K deficiency.\n\nExclusion Criteria:\n\nPatients with any of the following will not be eligible for participation:\n\n* Competing cause of acute liver injury such as hepatic ischemia that is felt by the investigator to be the primary reason for observed liver injury and supported by laboratory tests, serologies, liver biopsy, or radiology.\n* Known, pre-existing autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease which may confound the ability to make a diagnosis of DILI.\n* Acetaminophen hepatotoxicity.\n* Liver\u002Fbone marrow transplant prior to the development of drug- or CAM-induced liver injury.",{"count":368,"type":22},4000,"The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.",[28],[372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388],"Complementary and alternative medicine","Complementary therapies","Alternative therapies","Prescription Drugs","Non prescription Drugs","Liver Disease","Chemical Ind","Phenotype","Proteomics","Metabolomics","Cholestatic Liver Injury","Hepatocellular Liver Injury","Mixed Liver Injury","Matched Case Control Studies","Genotype","Liver Dis","Chem Ind","2026-04-06",{"date":391,"type":37},"2026-04-08",{"date":393,"type":37},"2004-09",{"date":250,"type":22},{"name":396,"class":97},"Duke University",6,{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":154},"100566029","NCT06649864","Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications","A Phase I Study of Autologous Adipose-derived Mesenchymal Stromal Cells in Preventing Biliary Complications After Living Donor Liver Transplant","Inclusion Criteria\n\n* Listed for liver transplantation\n* Non-pediatric patients with a planned LDLT\n* Ability to communicate with investigative staff\n* Competence to give written informed consent\n* Ability to comply with the entire study procedure\n* All sexes and genders will be eligible for the study\n\nExclusion Criteria\n\n* Planned deceased donor liver transplantation\n* Uncontrolled \u002F unresolved local or systemic infection\n* Body mass index \\> 40\n* Planned pancreaticoduodenectomy or sleeve gastrectomy\n* Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below)\n* Pregnancy or breastfeeding\n* Non-liver cancers (we will include certain patients with primary liver cancer as detailed below)\n* Treatment with any investigational drug \u002F device within 60 days prior to study entry\n* Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs\n* Patients who are employees or relatives of the investigator","65 Years",{"count":406,"type":22},20,[108],"The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.",[410,28],"Liver Transplant; Complications","2026-03-31",{"date":389,"type":37},{"date":414,"type":22},"2027-02",{"date":94,"type":22},{"name":417,"class":97},"Mayo Clinic",{"id":419,"slug":4,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":424,"studyType":136,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":4},"100627170","NCT07445152","Research on Construction and Verification of Multimodal Medical Imaging Large Model","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years.\n* Patients who underwent imaging examinations (CT, MRI, ultrasound, etc.) at this hospital during the study period.\n* The examination items are consistent with the disease types or systems focused on by the study (hepatobiliary and pancreatic system).\n* Possess at least complete imaging data, radiological diagnostic reports, with relevant medical record information as supplementary modalities.\n* Patients and their legal representatives have signed an informed consent form, agreeing to the use of their de-identified data for scientific research model validation.\n\nExclusion Criteria:\n\n* Patients who refuse to sign the informed consent form.\n* Cases with unassessable images due to severe motion artifacts, incomplete scanning, or equipment abnormalities.\n* Cases with severe deficiency of clinical data or failure to match with imaging data.\n* Cases with special pathological conditions or post-operative status (e.g., extensive resection, significant structural changes after radiotherapy) that affect the consistency of model analysis.\n* Data samples with privacy protection or legal risks.",{"count":208,"type":22},"4 Weeks","With the accumulation of multimodal clinical data such as medical imaging and electronic health records (EHRs), efficient utilization of multi-source information to achieve precise diagnosis and intelligent decision-making has become a core direction of medical artificial intelligence (AI). Although traditional unimodal algorithms have yielded outcomes in specific tasks, their inability to model the semantic correlations among imaging, textual, and laboratory data leads to insufficient stability and limited interpretability of diagnostic results, making it difficult to meet the needs of comprehensive decision-making in complex clinical scenarios.\n\nIn recent years, multimodal large models have demonstrated excellent cross-modal understanding and knowledge transfer capabilities in natural images and general vision-language tasks, providing a new paradigm for medical AI. However, direct application in medical scenarios still faces challenges: first, the medical semantic system differs significantly from general language models, hindering the accurate representation of disease characteristics and imaging details; second, the complex morphology of lesions and uneven sample distribution in medical data increase the difficulty of model generalization; third, clinical data involves privacy, so data security and ethical compliance serve as prerequisites for research.\n\nThe research on medical multimodal large models aims to integrate multi-source heterogeneous medical data, establish a unified semantic representation and reasoning mechanism, and realize full-process intelligent analysis including disease identification and lesion localization. This approach can not only improve the efficiency and accuracy of clinical diagnosis but also provide clinicians with interpretable and traceable auxiliary decision support, boasting broad application prospects.\n\nBased on the hospital's clinical data resources and the research team's algorithmic foundation, this study intends to construct a multimodal large model system for medical imaging diagnosis, enabling closed-loop intelligent analysis from multimodal information fusion to diagnostic report generation. The research will strictly adhere to medical ethical standards, protect patients' right to information, right to privacy, and data security. Before the official launch of the project, ethical review must be passed, and relevant regulations shall be followed to ensure the unity of scientific research and ethics, laying a compliant foundation for subsequent clinical validation and promotion.",[28,427,428,429],"Gallbladder Diseases","Pancreatic Diseases","Artificial Intelligence (AI)","2026-02-26",{"date":432,"type":37},"2026-03-03",{"date":434,"type":22},"2026-11-15",{"date":436,"type":22},"2027-11-15",{"name":438,"class":97},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":440,"slug":4,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":125},"100623719","NCT07400289","Development of a FibroScan Liver Examination Using a Single Probe","M149 - Development of a FibroScan Liver Examination Using a Single Probe","M149","Inclusion Criteria:\n\n* Adult patients (≥ 18 years of age).\n* Patient followed with a chronic liver disease.\n* Adult patient able to give his written consent.\n* For European sites: patient affiliated to the healthcare system.\n\nExclusion Criteria:\n\n* Vulnerable patients.\n* Patients with ascites.\n* Patients with heart failure.\n* Patients with acute hepatitis.\n* Patients with biliary obstruction.",{"count":447,"type":22},309,[25],"This is an exploratory, international, prospective, interventional, multicenter clinical investigation that will take place in 1 Hong Kong site and 3 French sites and 309 adults patients will be included. The study objective is to assess the LSM reproducibility between the FibroScan examination performed with the Single Probe (SP) and the FibroScan examination performed with the reference probes (M and XL).",[28],[452,453,454],"FibroScan","Liver stiffness Measurement","Vibration Controlled Transient Elastography","2026-02-03",{"date":457,"type":37},"2026-02-10",{"date":459,"type":37},"2025-11-14",{"date":301,"type":22},{"name":462,"class":124},"Echosens",{"id":464,"slug":4,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":154},"100536798","NCT06269510","Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients","Enhancing Alcohol Treatment Engagement in ALD Patients","ENGAGE-ALD","Inclusion Criteria:\n\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Willing and able to provide informed consent\n* Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals\n* Documented diagnosis of alcohol-related liver disease (ALD) (per protocol)\n* Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record.\n* No alcohol use treatment within the past 1 month including, but not limited to:\n\n  * Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use.\n  * Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery)\n  * Community-based church support groups primarily focused on alcohol abstinence or reduction in use.\n  * Residential (inpatient) alcohol treatment\n  * Intensive outpatient programs\n  * Any telehealth version of the above options\n* Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling\u002Fdata plan at no cost to subject by the study team for the duration of the research stud.\n* Ability to speak and comprehend English\n\nExclusion Criteria:\n\n* Unable to provide voluntary informed consent for any reason\n* Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \\>=10 on the Short Blessed Test for cognitive impairment.\n* Unable to read or understand English\n* Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation\n* Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine\n* Any other medical condition or circumstance that precludes safe and meaningful participation in the study\n* History of nonadherence to previous clinical or research studies",{"count":471,"type":22},268,[25],"The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.",[475,28],"Alcohol-related Liver Disease",[477,478,479,480,481,482],"Online web application","Engagement","Alcohol use disorder (AUD) treatment","Alcohol-related cirrhosis","SMART trial","Behavioral treatment","2026-01-30",{"date":455,"type":37},{"date":486,"type":37},"2026-01-28",{"date":488,"type":22},"2030-02",{"name":490,"class":97},"Henry Ford Health System",{"id":492,"slug":4,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":235,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":502,"conditions":503,"keywords":511,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":282},"100579393","NCT06823713","RTX001 Autologous Engineered Macrophages for Liver Cirrhosis","An Open-label Phase 1\u002F2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)","EMERALD","Individuals eligible to participate in this study must meet the following criteria:\n\nInclusion Criteria:\n\n1. Male or female age ≥18-75 years.\n2. Patient confirms willingness\u002Fability to comply with all study procedures.\n3. Diagnosis of liver cirrhosis based on at least one of:\n\n   1. Clinical and radiological features that correlate with a diagnosis of cirrhosis.\n   2. Transient elastography (Fibroscan) \\>15 kPa.\n   3. Previous liver biopsy confirming histological features of cirrhosis.\n4. Aetiology of liver disease of steatotic liver disease including MASLD or Met-ALD or ALD\n\n   a. Participants with alcohol-related liver disease (ALD or Met-ALD) only if they are confirmed to not be drinking alcohol above Met-ALD limits defined in this protocol. (N.B. No more than 34% of the total treated participants in this protocol will be ALD \\[excludes Met-ALD\\]).\n5. Hospitalised as an inpatient for a recent major hepatic decompensation event including ascites, hepatic encephalopathy, variceal bleed, HRS-AKI or SBP, this being the only hospitalisation for an hepatic decompensation event hospitalisation within the last 6 months, and where recent is defined as within 6 weeks of hospital discharge.\n6. Outpatient: Medically refractory ascites (ONLY), that recurs (i.e., second therapeutic LVP) within a 6-month period. Medically refractory ascites is defined by the repeated (≥2) need for LVP (i.e., therapeutic, not diagnostic) at least once per 8 weeks despite best medical attempts to control the ascites by sodium restriction and diuretic treatment, as confirmed by the Investigator. Onset is defined as the date of the second therapeutic LVP.\n7. Confirmatory PEth alcohol test \\\u003C200 ng\u002Fml\n8. MELD score of 12-20 taken within two weeks of 'qualifying' decompensation event.\n9. No known contradictions to filgrastim or leukapheresis procedure.\n10. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n11. Willing and able to give signed informed consent, and if applicable assent.\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nExclusion Criteria:\n\n1. Liver cirrhosis due to:\n\n   1. any viral hepatitidies, or\n   2. autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis.\n2. Acute liver disease in the absence of underlying liver cirrhosis, including, but not limited to, drug induced liver injury.\n3. Any current organ failure requiring more than outpatient supportive care, and not associated with the participant's qualifying hepatic decompensation event.\n4. Known splenomegaly ≥16 cm.\n5. Thrombocytopenia \\\u003C50×109\u002FL.\n6. Presence or suspicion of any of the following co-morbidities:\n\n   1. History of liver transplantation or other organ transplant.\n   2. ACLF.\n   3. Sepsis (with positive microbial cultures) or as defined by the Principal Investigator, unless stable and is at least 4 weeks after having completed a full course of IV antibiotics.\n   4. Known human immunodeficiency virus.\n   5. Known syphilis.\n   6. Known human T-lymphotropic virus 1.\n   7. Pulmonary embolism.\n   8. Hepatocellular carcinoma, or any active malignant disease within the last five years, (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, benign polyps etc.).\n   9. Co-hepatic morbidities e.g., portal vein thrombosis.\n   10. Participants with hepatic hydrothorax are excluded unless it is a small hydrothorax, not clinically apparent, that is detected incidentally by radiologic evaluation that does not require clinical intervention.\n   11. Chronic renal impairment (on dialysis) or unresolved AKI.\n   12. Acute or chronic heart failure (New York Heart Association Grade III\u002FIV).\n   13. Porto-pulmonary hypertension.\n   14. Severe chronic lung disease e.g., chronic obstructive pulmonary disease or interstitial lung disease where the forced expiratory volume in the first second (FEV1) is less than 50% and\u002For FEV1\u002Fforced vital capacity is less than 60%.\n   15. Hepatopulmonary syndrome.\n   16. Previous or current treatment with multiple infusions of albumin for therapeutic intent. \\[Use of albumin infusion at the time of large volume paracentesis for circulatory support is allowed.\\]\n   17. Significant untreated\u002Funstable psychiatric disease.\n   18. Transjugular intrahepatic portosystemic shunt (TIPSS).\n7. As judged by the Investigator, any evidence of intercurrent illness that is either life threatening or of clinical significance such that it might limit compliance with study procedures.\n8. Current or planned use of immunomodulators or immunosuppressive medication; note: low doses of corticosteroids up to 10 mg\u002Fkg\u002Fday prednisone or equivalent are permitted, or inhaled steroids to manage asthma.\n9. Received a gene or cell therapy at any time.\n10. Current or planned use of a live attenuated vaccines four weeks or fewer prior to enrolment (and for 3 months after the last administered dose of RTX001).\n11. Received any investigational product within the past 6 months, or five half-lives (whichever is longer) or participated in another investigational interventional study within 30 days prior to the screening visit.\n12. Participants with a known hypersensitivity to dimethyl sulfoxide (DMSO).\n13. Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.\n14. For female participants only - pregnant or breast-feeding or plans to become pregnant over the next year, or of childbearing potential and unwilling to comply with contraceptive requirements.\n15. Alcohol misuse in the period between identification of the participant as potentially suitable for this study to Screening (Visit 1), defined as alcohol intake greater than three units\u002Fday for females and four units\u002Fday for males, or binge drinking (\\>14 units\u002Fday) as determined by the Investigator. N.B. One unit is equivalent to 14 g of alcohol: a half-pint (\\~240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.\n16. Intake of non-medically supervised drugs of abuse that are judged (by the Investigator) to be a high risk to the participants acute health or which makes the participant likely to be non-compliant with follow-up.",{"count":499,"type":22},30,[108,501],"PHASE2","The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.",[504,505,506,28,507,508,509,510],"End-stage Liver Disease (ESLD)","Cirrhosis, Liver","Cirrhosis, Decompensated","Fibrosis and Cirrhosis of Liver","Decompensated Liver Cirrhosis","Decompensated Cirrhosis","Steatotic Liver Disease",[512,513,514,515,58,508,516,517,518,519,520,521,522,523,524,525,526,510],"Liver cirrhosis","Cirrhotic","Hepatic Cirrhosis","Chronic Liver Disease","Child-Pugh Score","MELD Score","Liver Function Tests","Hepatic Encephalopathy","End Stage Liver Disease (ESLD)","Variceal Bleeding","Jaundice","Retractable Ascites","Autologous","Cell Therapy","Macrophage","2026-01-27",{"date":486,"type":37},{"date":530,"type":37},"2024-10-15",{"date":532,"type":22},"2028-11-29",{"name":534,"class":535},"Resolution Therapeutics Limited","NETWORK",{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":154},"100459548","NCT05264051","MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease","Inclusion Criteria:\n\n* Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated\n\nExclusion Criteria:\n\n* \\\u003C18 yrs. of age",{"count":542,"type":22},1200,"The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.",[28],"2026-01-12",{"date":547,"type":37},"2026-01-14",{"date":549,"type":37},"2022-04-18",{"date":551,"type":22},"2027-03-01",{"name":553,"class":97},"University of Chicago",{"id":555,"slug":4,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":161,"studyType":136,"phases":4,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":154},"100556323","NCT06523608","Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease","Prediction of Decompensation and HCC Development in Patients With Advanced Chronic Liver Disease by the PLEASE and M10S20 Algorithms","DETECT","Inclusion Criteria:\n\n* The patient admitted\u002Freferred to study center is hospitalized or is an outpatient with advanced chronic liver disease (based on the BAVENO criteria)\n\nExclusion Criteria:\n\n* Pregnancy\n* Age \\\u003C18\n* Evidence of current malignancy except for non-melanocytic skin cancer\n* Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (New York Heart Association (NYHA) \\> II); severe chronic pulmonary disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) \\> III), severe neurological and psychiatric disorders).\n* Human Immunodeficiency Virus (HIV) positive patients.\n* Previous liver or other transplantation.\n* Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.\n* Physician's denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).",{"count":562,"type":22},600,"The aim of this observational study is to predict the short- and long-term development of acute severe disease events, de novo hepatocarcinoma (HCC) and mortality in patients with advanced chronic liver disease using the M10S20 (Liver stiffness and Model for End-Stage Liver Disease Score \\[MELD\\] combined) and PLEASE (Platelet, Etiology, Age, Sex und Elastography) scores, as well as the validation of the cost-effectiveness of the algorithm.\n\nPatients in this study are randomly divided into two groups:\n\n* Control group: patients are examined according to the current clinical standard protocol (biannual follow-up).\n* Stratified surveillance program:\n\n  * High-risk patients will receive an appointment for a hospital visit every 3 months.\n  * Low-risk patients could receive an appointment in one year. When necessary, if decompensation develops or HCC occurs, patients could be followed-up more frequently.",[28,565,566,567],"Hepatocellular Carcinoma","Hepatocarcinoma","Advanced Chronic Liver Disease","2025-12-15",{"date":570,"type":37},"2025-12-22",{"date":572,"type":37},"2024-09-01",{"date":199,"type":22},{"name":575,"class":97},"University Hospital Muenster",{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":154},"100583037","NCT06871111","The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial","MARCO","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of liver disease, liver failure, and\u002For cirrhosis\n* All patients will be hospitalized and have a hepatology consult in place.\n* They will be identified as having liver disease, liver failure, and\u002For cirrhosis based on a combination of at least one of the following:\n\n  * Labs demonstrating elevated liver chemistries (AST and ALT), elevated serum bilirubin levels, prolonged INR, or radiologic evidence of cirrhosis (e.g. nodular liver contour);\n  * Liver biopsy results; and\u002For\n  * Clinical or radiologic evidence of portal hypertension (e.g. splenomegaly, known varices, ascites, or hepatic venous pressure gradient ≥ 10mmHg).\n  * All diagnoses will be confirmed by the attending hepatologist's interpretation and consult note attestation.\n* Admitted to the hospital for hepatic decompensation\n* MELD score ≤ 30 at time of enrollment\n* Subject has ≤ 700µM butyrate and ≤ 10µM deoxycholate in fecal sample\n\nExclusion Criteria:\n\n* MELD score \\>30 at time of enrollment\n* Patients receiving any antibiotics for treatment of an infection.\n* Chronic or prophylactic antibiotic administration other than rifaximin, ciprofloxacin, or trimethoprim-sulfamethoxazole.\n\n  -Rifaximin will be either temporarily held or switched to another non-antibiotic therapy (e.g. lactulose or sodium benzoate) during the treatment phase of the trial. Potential subjects in whom the treating hepatologist deem it unsafe to pause or switch from Rifaximin therapy during the 7-10 day treatment phase will be excluded from the study.\n* Patients who are currently admitted to the intensive care unit for vasoactive support or mechanical ventilation.\n* Patients meeting the North American Consortia for Study of End Stage Liver Disease (NACSELD) criteria for acute-on-chronic liver failure (ACLF) with ≥ 2 organ failures by NACSELD-ACLF criteria at time of enrollment.\n* Patients with known intestinal barrier dysfunction, including active GI bleeding, enteropathy (including celiac disease), clinically active inflammatory bowel disease (Crohn's or Ulcerative Colitis), ischemic colitis, microscopic colitis, graft versus host disease (GVHD), or gastrointestinal malignancy.\n\n  o Active inflammatory bowel disease (IBD) will be defined based on a combination of:\n  * Symptoms (diarrhea and\u002For abdominal pain without another explanation)\n  * Laboratory evidence of inflammation (e.g. elevated CRP or fecal calprotectin without another explanation); and\n  * Either radiologic, endoscopic, and\u002For histologic evidence of active IBD.\n  * If IBD is suspected, this will be investigated with the general GI consult service prior to approaching for enrollment.\n  * If patients carry a diagnosis of IBD but do not meet the above criteria, they will be eligible for enrollment unless their IBD is managed with a systemic immunosuppression medication (e.g. anti-TNF-alpha therapy).\n  * If any form of the above intestinal disorders is suspected, they will be investigated with the general GI consult service prior to approaching for enrollment.\n* Profoundly immunocompromised patients, including patients with primary immunodeficiency, solid organ transplant recipients, any history of hematopoietic stem cell transplant (HSCT), ongoing cancer treatment, neutropenia \\\u003C 500 cells\u002Fmm3, HIV untreated or with CD4 \\\u003C 200 cells\u002Fmm3, immunosuppressive medications, including rituximab, anti-cytokine therapy, anti-rejection medications, chronic corticosteroids (a dose ≥ 20mg of prednisone daily for ≥ 1 month), biologic therapy for autoimmune condition.\n* Patients with delayed gastrointestinal motility as evidenced by ≤ 2 bowel movements per week at the time of enrollment.\n* Patients who are allergic to both ampicillin\u002Fsulbactam and meropenem.\n\n  * These are the two empiric antibiotic therapies that every strain is susceptible to.\n  * If a patient is allergic to only one of these medications, they may still be approached for enrollment.\n* A history of allergy to any of the investigational products\u002Fcomponents.\n* Patients with liver disease from Hepatitis C.\n* Patients with existing inflammatory arthritis.\n* History of total colectomy.\n* Patients who do not intend to continue their care on a routine basis at the University of Chicago beyond 6 months from the time of enrollment.\n* Patients with untreated psychiatric conditions, including illicit substance use disorders, that may interfere with reliable follow-up.\n* Unable to participate based on medical judgement of the care team.\n* Special populations:\n\n  * Women of childbearing age will have a:\n\n    * Negative serum pregnancy test at screening\n    * Use a medically acceptable and highly effective method of birth control for at least 6 weeks following completion of treatment.\n  * Another investigational drug or LBP:\n\n    * Prior use will be permitted;\n    * Concurrent use will preclude enrollment;\n    * Use will be restricted for the duration of the study (12 months after commensal consortia completion)\n  * Patients who are prescribed ACE-inhibitors and receive a consortium containing C. comes will receive more frequent blood pressure monitoring.\n  * Patients who are prescribed metformin will require either:\n\n    * Switch to another medication for diabetes control; or\n    * More frequent Vitamin B12 monitoring at 1, 3, 6, and 12 months of enrollment.\n* If a Vitamin B12 deficiency is discovered, it will be repleted as clinically indicated.",{"count":583,"type":22},24,[108],"The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study intervention is 1 of 9 novel live Commensal Consortia each containing eight commensal bacterial strains derived from healthy donors. The primary objective of the study is to determine safety and tolerability of Commensal Consortia administration.",[28,587,505],"Liver Failure","2025-11-03",{"date":590,"type":37},"2025-11-04",{"date":592,"type":37},"2025-08-04",{"date":594,"type":22},"2028-02-04",{"name":553,"class":97},{"id":597,"slug":4,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":125},"100495640","NCT05733832","A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease","A Randomized Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease","TLC","Inclusion Criteria:\n\n1. Male or female age ≥18\n2. Diagnosis of advanced liver disease, defined as either (must meet either a or b)\n\n   1. cirrhosis based on (either i or ii):\n\n      * biopsy\n      * characteristic clinical, laboratory, and imaging findings\n   2. acute alcoholic hepatitis, defined by NIAAA Alcoholic Hepatitis Consortia, as\n\n      * onset of jaundice (serum bilirubin \\>3.0 mg\u002FdL) in prior 8 weeks\n      * consumption of \\>40 (female) or 60 (male) g alcohol\u002Fday for ≥6 months, with \\\u003C60 days abstinence before jaundice onset,\n      * AST\\>50 IU\u002FL, AST\u002FALT\\>1.5, and both values \\\u003C400 IU\u002FL\n      * liver biopsy confirmation in patients with confounding factors\n3. Has at least one of the following complications due to advanced liver disease occurring during hospitalization:\n\n   1. ascites requiring diuretics or paracentesis\n   2. hepatic encephalopathy requiring lactulose or rifaximin\n   3. gastrointestinal bleeding due to portal hypertension\n   4. jaundice\n4. Has planned discharge alive to home or a facility within 72 hours of informed consent\n5. Able and willing to provide informed consent\n\nExclusion Criteria:\n\n1. discharge under hospice\n2. listed for liver transplant with MELD-Na ≥ 35\n3. unable or unwilling to participate in post-discharge follow-up either in-person or virtually\n4. unable to speak or understand English and\u002For Spanish\n5. low hearing or communicative ability (examiner rated) that would interfere with interventions and outcome assessments\n6. lack of access to a telephone\n7. incarcerated\n8. concurrent enrollment in an interventional research study",{"count":164,"type":22},[25],"Patients with complications of advanced liver disease often have difficulties after hospital discharge that result in early hospital readmission. Poor outcomes for these patients during this transitional time could be improved through the use of innovative transitional care models. This proposal aims to examine the effect of a transitional care model, The Transitional Liver Clinic (TLC), in reducing hospital re-admissions, improving quality of life, and improving patient experience.",[28],"2025-10-22",{"date":609,"type":37},"2025-10-24",{"date":611,"type":37},"2023-09-01",{"date":613,"type":22},"2028-06-30",{"name":615,"class":97},"Indiana University",{"id":617,"slug":4,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":623,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":635,"locationsCount":637},"100409625","NCT04613921","Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs","Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs","CHANCE","Inclusion Criteria:\n\n* 1\\. Male or female subject ≥18 years of age.\n\n  2\\. Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology).\n\n  3\\. Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:\n* Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list.\n* Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD\\>20) at the time of listing.\n* Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation.\n\n  4\\. Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria\n\nExclusion Criteria:\n\n\\-",{"count":624,"type":22},3000,"Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.",[28,627,628,410],"Liver Cirrhosis","Acute-On-Chronic Liver Failure","2025-10-15",{"date":631,"type":37},"2025-10-20",{"date":633,"type":37},"2021-07-08",{"date":301,"type":22},{"name":636,"class":97},"European Foundation for Study of Chronic Liver Failure",106,{"id":639,"slug":4,"hasResults":11,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":645,"conditions":646,"keywords":649,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":154},"100608780","NCT07206004","Effect of Parenteral Support on FibroScan in Short Bowel Syndrome","Effect of Parenteral Nutrition\u002FFluids on FibroScan Results in Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n* Adult patients (≥18 years) with short bowel syndrome with capacity to give consent\n* Patients receiving regular PS (≥4 days\u002Fweek and ≥10 liters\u002Fweek)\n* Stable clinical condition\n\nExclusion Criteria:\n\n* Known liver cirrhosis\n* Active infection, severe dehydration, or electrolyte disturbances\n* Pregnancy\n* Receiving IV fluids or medications on study day\n* Tapered infusion rate prior to disconnection",{"count":406,"type":22},"Home Parenteral Support (HPS) is a life-sustaining treatment for patients with short bowel syndrome and intestinal failure. This study aims to investigate how administration of parenteral support affects FibroScan results in order to determine optimal timing of liver assessment in this patient population.",[647,648,28],"Short Bowel Syndrome","Intestinal Failure",[452,650,651,652,653],"transient elastography","parenteral nutrition","intestinal failure","hepatic fibrosis","2025-09-25",{"date":656,"type":37},"2025-10-03",{"date":658,"type":22},"2026-02",{"date":660,"type":22},"2027-08",{"name":662,"class":97},"Rigshospitalet, Denmark",{"id":664,"slug":4,"hasResults":11,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":23,"phases":672,"briefSummary":673,"conditions":674,"keywords":675,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":154},"100527783","NCT06152250","Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis","Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis by Transcriptomics, Immunophenotyping and Functional Proteomics: Profil-NASH","Profil-NASH","Inclusion Criteria:\n\n* patient with a clinical diagnosis of NAFLD: steatosis detected on imaging and exclusion of secondary causes of steatosis (drugs, genetics, alcohol consumption \\>30 g\u002Fd in men and 20 g\u002Fd in women, chronic viral infection), in the absence or presence of an associated metabolic syndrome\n* and with significant liver fibrosis (≥ F2) on at least one non-invasive test (FibroScan®, Fibrometer®, NAFLD Fibrosis Score);\n* Patient of legal age (age ≥ 18 years);\n* Patient willing to undergo liver biopsy ;\n* Patient consenting to inclusion in the study after being informed and obtaining written consent;\n* Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Decompensated cirrhosis or clinically significant portal hypertension (clinical, radiological or endoscopic signs of portal hypertension; presence of hepatocellular insufficiency);\n* Secondary causes of steatosis, including chronic viral hepatitis, drugs, excessive alcohol consumption according to World Health Organization (WHO) criteria (\\> 30 g\u002Fd in men and 20 g\u002Fd in women), genetic mutations;\n* Any other cause of liver disease: genetic hemochromatosis, autoimmune liver disease, etc. (non-exhaustive list);\n* Presence of HCC at the time of inclusion;\n* Contraindications to liver biopsy (identical to those for FNA): coagulation disorders, biliary tract dilatation, intrahepatic tumor;\n* Pregnant, parturient or breast-feeding women;\n* Persons deprived of their liberty by judicial or administrative decision;\n* adults under legal protection (guardianship, curators).",{"count":671,"type":22},60,[25],"Non-alcoholic fatty liver disease (NAFLD) is a nosological entity that groups together non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Unlike NAFL, NASH is characterized by intrahepatic inflammation, and is solely at risk of progression to cirrhosis and hepatocellular carcinoma (HCC).\n\nIt is currently estimated that NAFLD affects approximately 25% of the world's adult population, and its incidence is rising in all regions of the world. Nevertheless, of all patients with NAFLD, only \\~25% have NASH.\n\nIdentifying patients with NASH is therefore crucial, determining the need for follow-up to detect the onset of fibrosis and\u002For HCC, and eventual access to therapeutic trials. Furthermore, intrahepatic inflammation, the initial driver of NASH, appears to play an important role in the development of fibrosis and HCC, which can occur in the absence of cirrhosis in these patients. However, few studies have been carried out in humans to date, with data mainly coming from mouse models.\n\nAn innovative technique, Fine-Needle Aspiration (FNA), enables to obtain cells from the liver compartment, including large numbers of immune cells. In participants with NAFLD and indication of liver biopsy, a FNA will also be performed. Forty patients will be included, with \\~75% of NASH and \\~25% of NAFL expected. The investigators will study the phenotypic and functional characteristics of human intrahepatic inflammatory cells obtained by the FNA with different innovative techniques (RNAseq, multiparameter immunophenotyping, single-cell secretome and phosphoproteome). Peripheral Blood Mononuclear Cells and circulating microRNAs, known to regulate immune responses, will also be analysed.\n\nThe hypothesis of Profile-NASH is that intrahepatic inflammatory profiles differ between NASH and NAFL, and is associated with fibrosis progression and carcinogenesis.\n\nThis pilot study, based on high-definition technologies, will provide precise new insights into the quality of intrahepatic inflammation and the mechanisms favoring the transition from NAFL to NASH and its progression. Precise analysis of the intrahepatic inflammatory microenvironment will enable the investigators to identify new players in the pathogenesis of NASH, and potential future therapeutic targets.",[28],[676,677,678,679],"intra-hepatic immune responses","liver inflammation","non-alcoholic fatty liver","Non-alcoholic fatty liver disease","2025-09-17",{"date":682,"type":37},"2025-09-18",{"date":684,"type":37},"2023-01-29",{"date":686,"type":22},"2029-01-29",{"name":688,"class":97},"Hospices Civils de Lyon",""]